June 2014

Philips, salesforce.com ink agreement for cloud-based healthcare information technology

Monday, June 30, 2014

Royal Philips, a healthcare technology company, and salesforce.com, a provider of customer relationship management software, have announced a strategic alliance to deliver an open, cloud-based healthcare platform, leveraging Philips’ medical technology, clinical applications and clinical informatics and salesforce.com’s experience in enterprise cloud computing, innovation and customer engagement.

[Read More]

India’s generics industry hires consultant to boost image

Monday, June 30, 2014

Companies specializing in generic pharmaceuticals in India and the U.S. have retained India First Group to promote the benefits of affordable access to medicine as vital to improving healthcare worldwide. India First Group is a strategic advisory firm based in Washington, D.C. and New Delhi that assists U.S. companies pursuing business opportunities in India and supports Indian companies investing in the U.S.

[Read More]

Chesapeake Urology raises $100,000 for Urology Care Foundation

Monday, June 30, 2014

Sanford Siegel, M.D., president and CEO of Chesapeake Urology Associates, presented the Urology Care Foundation with $114,248 in support of its prostate cancer research efforts. The funds were raised through the Zero Prostate Cancer Challenge (ZPCC) 10K/5K run in September 2013. The Urology Care Foundation is the official foundation of the American Urological Association (AUA)—an organization of roughly 20,000 urologists.

[Read More]

FDA approves Afrezza to treat diabetes

Monday, June 30, 2014

The FDA has approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal.

[Read More]

Ampio Pharmaceuticals closes enrollment in the OptimEyes study

Friday, June 27, 2014

Ampio Pharmaceuticals has informed the Transplant and Ophthalmology Division of the FDA of its intent to reduce the patient sample size in the OptimEyes study for the treatment of diabetic macular edema (oral treatment with Optina). This trial was intended to enroll 450 patients and was powered at 95%. The present enrollment of over 355 patients provides an adequate power of 88%, which the company believes is more than sufficient for statistical evaluation.

[Read More]

Aurinia Pharmaceuticals initiates phase IIb trial of Voclosporin for lupus nephritis

Friday, June 27, 2014

Aurinia Pharmaceuticals has enrolled the first patient in its planned phase IIb clinical trial to evaluate the efficacy of voclosporin as a treatment for lupus nephritis (LN). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition. The Lupus Foundation of America believes there are as many as 1.5 million people in the U.S. with systemic lupus erythematosus (SLE), approximately 40% to 70% of whom will develop LN.

[Read More]

Jennifer Doudna, Emmanuelle Charpentier win award for biomedical research

Friday, June 27, 2014

Johnson & Johnson has named Dr. Jennifer Doudna of the University of California at Berkeley and the Howard Hughes Medical Institute, and Dr. Emmanuelle Charpentier, of the Hannover Medical School and Helmholtz Center for Infection Research (HZI), Germany and the Laboratory for Molecular Infection Medicine Sweden (MIMS), Umea University, Sweden, the winners of the 2014 Dr. Paul Janssen Award for Biomedical Research. Their collaboration led to the discovery of a new method for precisely manipulating genetic information in ways that should produce new insights in health and disease, and may lead to the discovery of new targets for drug development.

[Read More]